- Home
- INMB vs SACH Comparison
INMB vs SACH Comparison
Compare INMB & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- SACH
- Stock Information
- Founded
- INMB 2015
- SACH 2010
- Country
- INMB United States
- SACH United States
- Employees
- INMB N/A
- SACH N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- SACH Real Estate Investment Trusts
- Sector
- INMB Health Care
- SACH Real Estate
- Exchange
- INMB Nasdaq
- SACH Nasdaq
- Market Cap
- INMB 112.0M
- SACH 61.5M
- IPO Year
- INMB 2019
- SACH 2017
- Fundamental
- Price
- INMB $4.40
- SACH $1.22
- Analyst Decision
- INMB Strong Buy
- SACH Buy
- Analyst Count
- INMB 2
- SACH 2
- Target Price
- INMB $21.00
- SACH $2.25
- AVG Volume (30 Days)
- INMB 198.5K
- SACH 523.0K
- Earning Date
- INMB 10-31-2024
- SACH 11-14-2024
- Dividend Yield
- INMB N/A
- SACH 19.75%
- EPS Growth
- INMB N/A
- SACH N/A
- EPS
- INMB N/A
- SACH N/A
- Revenue
- INMB $42,000.00
- SACH $10,951,064.00
- Revenue This Year
- INMB N/A
- SACH N/A
- Revenue Next Year
- INMB N/A
- SACH N/A
- P/E Ratio
- INMB N/A
- SACH N/A
- Revenue Growth
- INMB N/A
- SACH N/A
- 52 Week Low
- INMB $4.32
- SACH $1.16
- 52 Week High
- INMB $14.74
- SACH $4.64
- Technical
- Relative Strength Index (RSI)
- INMB 37.57
- SACH 25.79
- Support Level
- INMB $4.74
- SACH $1.35
- Resistance Level
- INMB $5.16
- SACH $1.48
- Average True Range (ATR)
- INMB 0.38
- SACH 0.08
- MACD
- INMB -0.05
- SACH 0.01
- Stochastic Oscillator
- INMB 5.56
- SACH 15.58
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.